IRF3在复发缓解型MS患者中的表达下调

IF 0.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Sobhan Helbi, Zahra Engardeh, Sahar Nickbin poshtamsary, Z. Aminzadeh, N. Jivad
{"title":"IRF3在复发缓解型MS患者中的表达下调","authors":"Sobhan Helbi, Zahra Engardeh, Sahar Nickbin poshtamsary, Z. Aminzadeh, N. Jivad","doi":"10.3934/MEDSCI.2019.2.140","DOIUrl":null,"url":null,"abstract":"Background: Relapsing-Remitting (RRMS) is the most common Multiple Sclerosis disease course. Interferon regulatory factor 3 (IRF3) as major regulators of immune system genes plays a critical role in the activation of type I interferons promoters, in particular IFNβ promoter. Hence we aimed to evaluate the expression rate of IRF3 in RRMS patients under different type of IFNβ treatment. Material and methods: In the present study total of 100 subjects participated. Blood samples of 25 patients with RRMS newly diagnosed who have not been treated with interferon components, 25 patients with RRMS treated with Interferon beta-1α (B1a), 25 patients with RRMS treated with Interferon beta-1β (B1b) and 25 control samples were collected. The samples were transferred at standard conditions to the Cellular and Molecular Research Center of Shahrekord University of Medical Sciences, RNA was extracted and converted to cDNA. To evaluate the expression of IRF3 the Real-Time PCR method using SYBR Green dye was done. The level of gene expression was measured by a comparative threshold cycle formula. The obtained data were analyzed using SPSS v15 software. Results: In the study we compared the IRF3 mRNA expression of all subjects in association with gender, which no significant difference was seen (P > 0.05). Also assessment of the gene mRNA level in study groups revealed that the B1b, B1a and new case group had the lowest expression respectively. Moreover, comparison of the mRNA level between new case and B1b groups showed remarkable difference (P 0.05). Conclusion: Perhaps the IFNβ recombinants decreases the IRF3 expression as a negative feedback mechanism. Overall the data reported here, supports the previous studies in important role of IRF3 in autoimmune inflammatory disease of CNS and Multiple Sclerosis.","PeriodicalId":43011,"journal":{"name":"AIMS Medical Science","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2019-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Down-regulation of IRF3 expression in Relapse-Remitting MS patients\",\"authors\":\"Sobhan Helbi, Zahra Engardeh, Sahar Nickbin poshtamsary, Z. Aminzadeh, N. Jivad\",\"doi\":\"10.3934/MEDSCI.2019.2.140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Relapsing-Remitting (RRMS) is the most common Multiple Sclerosis disease course. Interferon regulatory factor 3 (IRF3) as major regulators of immune system genes plays a critical role in the activation of type I interferons promoters, in particular IFNβ promoter. Hence we aimed to evaluate the expression rate of IRF3 in RRMS patients under different type of IFNβ treatment. Material and methods: In the present study total of 100 subjects participated. Blood samples of 25 patients with RRMS newly diagnosed who have not been treated with interferon components, 25 patients with RRMS treated with Interferon beta-1α (B1a), 25 patients with RRMS treated with Interferon beta-1β (B1b) and 25 control samples were collected. The samples were transferred at standard conditions to the Cellular and Molecular Research Center of Shahrekord University of Medical Sciences, RNA was extracted and converted to cDNA. To evaluate the expression of IRF3 the Real-Time PCR method using SYBR Green dye was done. The level of gene expression was measured by a comparative threshold cycle formula. The obtained data were analyzed using SPSS v15 software. Results: In the study we compared the IRF3 mRNA expression of all subjects in association with gender, which no significant difference was seen (P > 0.05). Also assessment of the gene mRNA level in study groups revealed that the B1b, B1a and new case group had the lowest expression respectively. Moreover, comparison of the mRNA level between new case and B1b groups showed remarkable difference (P 0.05). Conclusion: Perhaps the IFNβ recombinants decreases the IRF3 expression as a negative feedback mechanism. Overall the data reported here, supports the previous studies in important role of IRF3 in autoimmune inflammatory disease of CNS and Multiple Sclerosis.\",\"PeriodicalId\":43011,\"journal\":{\"name\":\"AIMS Medical Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2019-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIMS Medical Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3934/MEDSCI.2019.2.140\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/MEDSCI.2019.2.140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:复发缓解(RRMS)是多发性硬化症最常见的病程。干扰素调节因子3 (IRF3)作为免疫系统基因的主要调节因子,在I型干扰素启动子,特别是IFNβ启动子的激活中起着关键作用。因此,我们旨在评估不同类型IFNβ治疗下RRMS患者中IRF3的表达率。材料与方法:本研究共纳入100名受试者。收集25例未接受干扰素成分治疗的新诊断RRMS患者、25例接受干扰素β -1α (B1a)治疗的RRMS患者、25例接受干扰素β -1β (B1b)治疗的RRMS患者和25例对照样本。在标准条件下将样品转移到Shahrekord医科大学细胞和分子研究中心,提取RNA并转化为cDNA。采用SYBR绿染料实时荧光定量PCR法检测IRF3的表达。通过比较阈值周期公式测量基因表达水平。采用SPSS v15软件对所得数据进行分析。结果:本研究比较了不同性别受试者IRF3 mRNA的表达,差异无统计学意义(P > 0.05)。同时对各研究组基因mRNA水平的评估显示,B1b组、B1a组和新病例组分别表达量最低。新病例组与B1b组mRNA水平比较差异有统计学意义(p0.05)。结论:IFNβ重组物降低IRF3表达可能是一种负反馈机制。综上所述,本文报道的数据支持了先前关于IRF3在中枢神经系统自身免疫性炎症性疾病和多发性硬化症中的重要作用的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Down-regulation of IRF3 expression in Relapse-Remitting MS patients
Background: Relapsing-Remitting (RRMS) is the most common Multiple Sclerosis disease course. Interferon regulatory factor 3 (IRF3) as major regulators of immune system genes plays a critical role in the activation of type I interferons promoters, in particular IFNβ promoter. Hence we aimed to evaluate the expression rate of IRF3 in RRMS patients under different type of IFNβ treatment. Material and methods: In the present study total of 100 subjects participated. Blood samples of 25 patients with RRMS newly diagnosed who have not been treated with interferon components, 25 patients with RRMS treated with Interferon beta-1α (B1a), 25 patients with RRMS treated with Interferon beta-1β (B1b) and 25 control samples were collected. The samples were transferred at standard conditions to the Cellular and Molecular Research Center of Shahrekord University of Medical Sciences, RNA was extracted and converted to cDNA. To evaluate the expression of IRF3 the Real-Time PCR method using SYBR Green dye was done. The level of gene expression was measured by a comparative threshold cycle formula. The obtained data were analyzed using SPSS v15 software. Results: In the study we compared the IRF3 mRNA expression of all subjects in association with gender, which no significant difference was seen (P > 0.05). Also assessment of the gene mRNA level in study groups revealed that the B1b, B1a and new case group had the lowest expression respectively. Moreover, comparison of the mRNA level between new case and B1b groups showed remarkable difference (P 0.05). Conclusion: Perhaps the IFNβ recombinants decreases the IRF3 expression as a negative feedback mechanism. Overall the data reported here, supports the previous studies in important role of IRF3 in autoimmune inflammatory disease of CNS and Multiple Sclerosis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AIMS Medical Science
AIMS Medical Science MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
14.30%
发文量
20
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信